Perivesical unicentric Castleman disease initially suspected to be metastatic prostate cancer

Guthrie, Patrick J; Thomas, John V.; Peker, Deniz; Türkbey, Barış; Rais‐Bahrami, Soroush

doi:10.4103/0974-7796.177196

Cited by 5 publications

(5 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…8,9 Delayed ferumoxytol imaging can also take advantage of intracellular uptake of the nanoparticles to image inflammation 10 or assess the lymph nodes for tumor staging. 11–14 …”

Section: Introductionmentioning

confidence: 99%

What Does the Boxed Warning Tell Us? Safe Practice of Using Ferumoxytol as an MRI Contrast Agent

Várallyay¹,

Tóth²,

et al. 2017

AJNR Am J Neuroradiol

View full text Add to dashboard Cite

Background and Purpose Despite the label change and FDA’s boxed warning added to the Feraheme® (ferumoxytol, AMAG Pharmaceuticals, Waltham, MA) label in March 2015, radiologists have shown increasing interest in using ferumoxytol as an MRI contrast agent as a supplement or alternative to gadolinium. The goals of this study are to provide information regarding ferumoxytol safety as an imaging agent in a single center, and to assess how Feraheme® label change may affect this potential, currently off label indication. Materials and Methods This retrospective study evaluated the overall frequency of ferumoxytol related adverse events (AEs) when used for CNS MRI. Subjects with various CNS pathologies were enrolled in Institutional Review Board approved imaging studies. Ferumoxytol was administered as multiple rapid bolus injections. The risk of AEs was correlated with demographic data/medical history. Results Safety of 671 ferumoxytol enhanced MR studies in 331 subjects was analyzed. No anaphylaxis, life-threating or fatal (grade 4 or 5) AE was recorded. The overall proportion of ferumoxytol related grade 1–3 AE was 10.6% (8.6% occurring within 48h), including hypertension (2.38%), nausea (1.64%), diarrhea (1.04%) and headache (1.04%). History of one or two allergies was associated with increased risk of AE (14.61% vs. no allergies of 7.51%, p=0.0069). Conclusion The frequency of mild ferumoxytol related AE was comparable with literature results, and no serious AE was recorded. While the recommendations in the boxed warning should be followed, serious AE appear to be rare events and with proper precautions ferumoxytol may be a valuable MRI agent.

show abstract

“…8,9 Delayed ferumoxytol imaging can also take advantage of intracellular uptake of the nanoparticles to image inflammation 10 or assess the lymph nodes for tumor staging. 11–14 …”

Section: Introductionmentioning

confidence: 99%

What Does the Boxed Warning Tell Us? Safe Practice of Using Ferumoxytol as an MRI Contrast Agent

Várallyay¹,

Tóth²,

et al. 2017

AJNR Am J Neuroradiol

View full text Add to dashboard Cite

show abstract

“…MRI findings generally show a mass that is relatively isointense to the skeletal muscle as hypointense on T1W and hyperintense on T2W and contrast enhancement after gadolinium; flow voids showed feeding vessels, but these characteristics are non-specific [5 , 6 , 8 , 11] . MRI is suitable for evaluating the extent of the disease and its relationship with adjacent structures, although with limited evaluation of calcifications.…”

Section: Discussionmentioning

confidence: 99%

“…Unicentric CD responded well to resection, which is considered as the standard treatment. The removal of unicentric CD is feasible in the majority of cases, and it is almost always curative [4] , even for cases arising from the pelvic lymph nodes; nearly 100% with 5 years survival [11] . However, recurrences have been reported, especially for incomplete resection [4] .…”

Section: Discussionmentioning

confidence: 99%

Unicentric Castleman's disease in the female pelvis

Đức

Doan

Huy

2020

Radiology Case Reports

View full text Add to dashboard Cite

Castleman's disease (CD) or angiofollicular lymphoid hyperplasia is a rare disorder with unknown aetiology that can easily be misdiagnosed as lymphoma, neoplasm, or infection. Diagnosis is challenging due to its non-specific symptoms and radiologic signs as well as its rarity. We report a case of a middle-aged woman with a mass adjacent to the uterus that was accidentally detected by ultrasound; it was believed to be of ovarian origin. Subsequently, the patient underwent a successful tumorectomy. Pathological examination confirmed the hyaline–vascular type of CD in a pelvic location. This was a typical case of an asymptomatic unicentric and hyaline–vascular type of CD.

show abstract

“…There is less vascular proliferation in comparison with hypervascular pattern [38]. Recently, two subtypes were described: HHV-8 associated type (especially in HIV-patients), and the multicentric not otherwise specified (NOS) type [39,40]. In the HHV-8 type, the lymph node architecture is generally normal and either follicle hyalinization or marked interfollicular vasculature can be noticed.…”

Section: Figure 6 -Castleman Disease Section Through the Mantle Zonementioning

confidence: 99%

“…After surgical removal, the clinical symptoms will disappear and the seric level of IL-6 decreases [48]. If the complete removal cannot be achieved, the alternative is represented by radiation therapy [40]. It is difficult to treat and completely eradicate the multicentric disease.…”

Section: Figure 6 -Castleman Disease Section Through the Mantle Zonementioning

confidence: 99%

Untitled

2020

Rom J Morphol Embryol

View full text Add to dashboard Cite

The most frequent tumoral condition of the uterus is represented by uterine myoma. The diagnosis, in most cases, is established by clinical examination and ultrasound scan. Nevertheless, there are rare cases, in which the surgical findings reveal a retroperitoneal tumor instead of a uterine myoma. These could be represented by schwannomas or Castleman disease. The schwannomas are rarely malignant and arise from the Schwann cells of nerve fibers. These tumors are frequently found at the level of the head, neck and mediastinum and rarely in the pelvis. Generally, schwannomas localized at retroperitoneal level are asymptomatic and with a very slow growth rate. The treatment consists in complete surgical resection. The recurrence rate is low and, generally, the prognosis is good. The Castleman disease is considered a rare entity, but it should be always taken into consideration when it comes to a differential diagnosis in a young patient who presents a retroperitoneal mass at imagery exams. The condition affects the lymphatic system and is characterized by a hyperplasia of the lymph nodes, sometimes associated with herpes virus infection. The clinical picture is often non-specific; the pain may be the only symptom. The imaging methods are not always conclusive for the final positive diagnosis and the histopathological examination is always necessary. Pelvic Castleman disease can be misdiagnosed as myoma or an adnexal tumor. In this article, we review the present knowledge regarding the pathogenesis, pathology and management of these rare retroperitoneal tumors. Both conditions, when located in pelvis must be taken into consideration in the differential diagnosis of uterine myomas, especially in the pedunculated form.

show abstract

Perivesical unicentric Castleman disease initially suspected to be metastatic prostate cancer

Cited by 5 publications

References 13 publications

What Does the Boxed Warning Tell Us? Safe Practice of Using Ferumoxytol as an MRI Contrast Agent

What Does the Boxed Warning Tell Us? Safe Practice of Using Ferumoxytol as an MRI Contrast Agent

Unicentric Castleman's disease in the female pelvis

Untitled

Contact Info

Product

Resources

About